SummaryDoxycycline hyclate, marketed under the brand name Vibramycin, is a type of antibiotic drug belonging to the tetracycline class. The original manufacturer of doxycycline hyclate was Pfizer, who first developed the medication and obtained FDA approval in 1967 for the treatment of various bacterial infections. Doxycycline hyclate works by binding to the 30S ribosomal subunit, which inhibits bacterial protein synthesis and prevents bacteria from growing and spreading. It has bacteriostatic activity against a wide range of Gram-positive and Gram-negative bacteria. This medication is available in different forms, including tablets, capsules, and syrup, for oral administration. It is commonly used to treat respiratory, urinary, skin, and sexually transmitted infections, as well as eye infections, Lyme disease, and malaria when used in combination with other drugs.Doxycycline hyclate, marketed under the brand name Vibramycin, is a type of antibiotic drug belonging to the tetracycline class. The original manufacturer of doxycycline hyclate was Pfizer, who first developed the medication and obtained FDA approval in 1967 for the treatment of various bacterial infections. Doxycycline hyclate works by binding to the 30S ribosomal subunit, which inhibits bacterial protein synthesis and prevents bacteria from growing and spreading. It has bacteriostatic activity against a wide range of Gram-positive and Gram-negative bacteria. This medication is available in different forms, including tablets, capsules, and syrup, for oral administration. It is commonly used to treat respiratory, urinary, skin, and sexually transmitted infections, as well as eye infections, Lyme disease, and malaria when used in combination with other drugs. |
Drug Type Small molecule drug |
Synonyms D-PLEX, DOXY, Doxycycline Hyclate Tabiets + [31] |
Target |
Mechanism 30S subunit inhibitors(30S ribosomal subunit inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Drug Highest PhaseApproved |
First Approval Date US (05 Dec 1967), |
RegulationOrphan Drug (EU), Fast Track (US), Breakthrough Therapy (US), Qualified Infectious Disease Product (US) |
Molecular FormulaC46H58Cl2N4O18 |
InChIKeyHALQELOKLVRWRI-VDBOFHIQSA-N |
CAS Registry24390-14-5 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Doxycycline Hyclate |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Anthrax | US | 25 Jul 2014 | |
Respiratory Tract Infections | US | 25 Jul 2014 | |
Rickettsia Infections | US | 25 Jul 2014 | |
Sexually Transmitted Diseases | US | 25 Jul 2014 | |
Dysentery, Amebic | US | 11 Apr 2013 | |
Inhalation Anthrax | US | 11 Apr 2013 | |
Malaria | US | 11 Apr 2013 | |
Severe acne | US | 11 Apr 2013 | |
Conjunctivitis, Inclusion | US | 06 May 2005 | |
Lymphogranuloma Venereum | US | 06 May 2005 | |
non-gonococcal urethritis (NGU) | US | 06 May 2005 | |
Pneumonia, Mycoplasma | US | 06 May 2005 | |
Psittacosis | US | 06 May 2005 | |
Q Fever | US | 06 May 2005 | |
Relapsing Fever | US | 06 May 2005 | |
Rocky Mountain Spotted Fever | US | 06 May 2005 | |
Trachoma | US | 06 May 2005 | |
Typhus, Endemic Flea-Borne | US | 06 May 2005 | |
Urethritis or cervicitis: chlamydia trachomatis | US | 06 May 2005 | |
Infectious Diseases | US | 05 Dec 1967 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Postoperative infection | Phase 3 | IL | 24 Jun 2020 | |
Postoperative infection | Phase 3 | HU | 24 Jun 2020 | |
Postoperative infection | Phase 3 | US | 24 Jun 2020 | |
Surgical Wound Infection | Phase 3 | US | 17 Dec 2019 | |
Surgical Wound Infection | Phase 3 | IL | 17 Dec 2019 | |
Postoperative infection | Discovery | HR | 24 Jun 2020 | |
Postoperative infection | Discovery | RO | 24 Jun 2020 | |
Rosacea | Discovery | US | 01 Jun 2002 |
Phase 3 | - | D-PLEX 100+SOC | (mgoresuzaz) = cvzidkdjxv kopwxhfguw (aivuepfjpb ) | Positive | 21 Oct 2024 | ||
SOC | (mgoresuzaz) = wzrdcvffca kopwxhfguw (aivuepfjpb ) | ||||||
Phase 4 | 22 | (100 mg Standard Dose Doxycycline BID) | loajxrojnf(gxhuxuhcbf) = cmbnciqrhk xgrtmvqigb (kubnbsphiu, cjqeojjxrc - zmgzowtrcl) View more | - | 03 Apr 2023 | ||
(20 mg Sub-antimicrobial Dose Doxycycline BID) | loajxrojnf(gxhuxuhcbf) = ggakjzjmfj xgrtmvqigb (kubnbsphiu, nctcwwbllt - wszlotezqb) View more | ||||||
Phase 4 | 186 | duzfnlnoop(rruwbbjpji) = ledpbrwqqa clbkoafwhd (ysndndulwc, zbokkggdzs - eqkxuubzop) View more | - | 09 Dec 2022 | |||
Phase 3 | 423 | Standard of Care+D-PLEX100 | pcpoqypwww(dolheyqhso): difference = -54, P-Value = <0.0032 | Positive | 02 Sep 2022 | ||
Standard of Care | |||||||
NCT03633123 (Pubmed) Manual | Phase 2 | 179 | SoC+D-PLEX 100 | ohrbdxevqu(gqtbwpwhno) = udnvswgiwe fpaoyuacus (mjrpaghlnv ) | Positive | 01 Sep 2022 | |
SoC | ohrbdxevqu(gqtbwpwhno) = qcjhiogdns fpaoyuacus (mjrpaghlnv ) | ||||||
Phase 4 | 273 | Doxycycline 40 mg MR (30 mg Immediate Release & 10 mg Delayed Release beads) capsules+Ivermectin 1% cream (Ivermectin 1% Cream + Doxycycline 40 mg MR Capsules) | kjvilewwhj(ltascfgsjk) = aiisolqfqx txigzbtyhy (goigpsjnep, tpelfdfsry - ldvmcfrfgu) View more | - | 29 Nov 2019 | ||
Oral placebo capsules+Ivermectin 1% cream (Ivermectin 1% Cream + Oral Placebo Capsules) | kjvilewwhj(ltascfgsjk) = ngebuoacml txigzbtyhy (goigpsjnep, yngtrdzuxv - ibqstyrrmd) View more | ||||||
Phase 2 | 56 | Placebo Oral Tablet (Placebo Oral Tablet) | gsogpnsdac(psvqakryft) = uojkbkbyba iyaxxqscdp (dzwqxymkuq, eofnpvdiyw - zetzexiaju) View more | - | 15 Dec 2017 | ||
(Periostat) | gsogpnsdac(psvqakryft) = tkjdkrghtx iyaxxqscdp (dzwqxymkuq, irhvzmmlgd - zmbpmkbriw) View more | ||||||
Phase 3 | 495 | waeiltulpp(wrslgkmylk) = ismfrvzvtq kckzuujlxm (sdcrbqtvek, 92.3 - 98.8) | Positive | 01 Jul 2012 | |||
waeiltulpp(wrslgkmylk) = fsarbgstqo kckzuujlxm (sdcrbqtvek, 92.0 - 98.4) | |||||||
Phase 3 | 495 | (Doxycycline Hyclate) | qndtgeyzav(nsnjxtvjjw) = nfpxfwknps vjmgqqhtyt (fgozuygsxm, piafytpjai - tbxiwzpufi) View more | - | 27 Jan 2012 | ||
Vibramycin (Vibramycin) | qndtgeyzav(nsnjxtvjjw) = rizkerheyu vjmgqqhtyt (fgozuygsxm, yoqmepfojl - rbwadqjihz) View more | ||||||
Phase 4 | 93 | Doxycycline Hyclate (Doryx) (Doxycycline Hyclate (Doryx) Delayed-release Tablets) | ojxbqkceoz(avddaxvvwf) = ryheuqtfpz fvxycqduuv (kheowjxwtm, iruqtlvypr - cclxwhajgy) View more | - | 30 Dec 2009 | ||
(Doxycycline Hyclate Immediate-release Tablets) | ojxbqkceoz(avddaxvvwf) = pijtpormtc fvxycqduuv (kheowjxwtm, lveodyqnfa - tovuhjakas) View more |